Ivosidenib and Azacitidine in IDH1-Mutated AML

N Engl J Med. 2022 Jun 30;386(26):2536. doi: 10.1056/NEJMc2206489.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Azacitidine* / therapeutic use
  • Glycine / analogs & derivatives
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Pyridines / therapeutic use

Substances

  • Pyridines
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Azacitidine
  • ivosidenib
  • Glycine